Ascend Diagnostics is a UK company based in Manchester, the birthplace of mass-spectrometry. Our office is located at Citylabs 1.0, a multi-million-pound development for scientific and biomedical companies.
We work with leading industry experts to advance clinical laboratory diagnostics using MALDI mass-spectrometry.
First ID platform installed
First fast microbial ID platform installed in a routine clinical laboratory in Marseille, France.
In Vitro Diagnostic (IVD) devices CE mark obtained, certifying that instrument complies the directive IVDD98/79/EC.
ISO 13485 full scope renewal
Renewal at full scope including Production, R&D, Administration, Sales and Service of the QMS standard for Medical Devices.
Accelerate Dx evaluation
Two systems placed at Accelerate Diagnostics for their evaluation.
Major overseas investment
Ascendx secures major overseas investment for the development of its next generation MALDI-TOF platform.
ASMS annual conference
Previewed first product at American Society for Mass Spectrometry (ASMS) Annual Conference.
The group re-branded the UK operation to take control of worldwide marketing and product strategy.
Secured major investment
ASTA UK and NosQuest (Korea) spun out from ASTA to focus on R&D and sales in OEM and organic growth markets, primarily in Europe and the USA.
Gained accreditation to ISO 13485
Regulatory compliance is maintained by a Product and Application Lifecycle and Enterprise Resource Planning management system, to optimise costs and workflow.
Modern PLM infrastructure
PTC's Windchill, a state-of-the-art Product Lifecycle Management software, was implemented to drive and control development processes.
ASTA UK Ltd
ASTA UK was founded in 2016. The company's aim was to critically evaluate the ASTA MALDI platform and prepare products for European and US markets.